Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

  • Technology appraisal guidance
  • TA329
  • Published: 

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: evaluation report

Table of contents

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Abbvie

03. Consultee comments on the ACD - Crohn's & Colitis UK

04. Consultee comments on the ACD - Crohn's & Colitis UK

05. Consultee comments on the ACD - British Society of Gastroenterology

06. Consultee comments on the ACD - British Society of Paediatric

07. Consultee comments on the ACD - British Society of Paediatric

08. Consultee comments on the ACD - Royal College of Nursing

09. Consultee comments on the ACD - Royal College of Physicians

10. Consultee comments on the ACD - United Kingdom Clinical Pharmacy Association

11. Public comments on the ACD received via the NICE website

12. Public comments on the ACD received via the NICE website

13. Public comments on the ACD received via the NICE website

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

 

This page was last updated: 10 December 2014